Influenza and RSV are two major respiratory infections impacting populations worldwide. Influenza Type A and B viruses drive seasonal epidemics and, at times, global pandemics, with strains like H1N1 and H3N2 causing significant public health challenges. Annually updated flu vaccines, based on recent surveillance data, are crucial for controlling these outbreaks. RSV, in contrast, primarily affects infants and the elderly, often leading to serious conditions such as bronchiolitis and pneumonia. Key RSV proteins, such as the Fusion (F) glycoprotein, which enables viral entry, and the Major Surface (G) glycoprotein, which facilitates viral attachment, are central to research and therapeutic development.
At AntibodySystem, we are committed to equipping researchers worldwide with premium Influenza and RSV proteins and antibodies. Our products support advanced virology research, delivering reliability, precision, and performance to drive discoveries in virus-host interactions, vaccine development, and therapeutic innovation.
Influenza Virus Proteins and Antibodies
Our Influenza virus product line includes a variety of high-purity recombinant proteins, such as:
■H1N1 Hemagglutinin (HA) – Designed to facilitate studies in viral entry mechanisms and immune response.
■H3N2 Hemagglutinin (HA) – Essential for understanding influenza virus structure and function, as well as for vaccine development.
■Neuraminidase (NA) – An ideal tool for studying viral replication and drug-target interactions.
Each Influenza protein in our lineup undergoes rigorous quality control to ensure activity, stability, and reproducibility, making them ideal for basic and translational research.
Fig1.Structure of Influenza A virus, highlighting Hemagglutinin (H) and Neuraminidase (N) proteins essential for viral entry and vaccine targeting
|
Type |
Catalog No |
Product Name |
|---|---|---|
|
Protein |
EVV03801 |
Recombinant Influenza A virus (H1N1) HA/Hemagglutinin Protein, C-His |
|
EVV03802 |
Recombinant Influenza A virus (H3N2) HA/Hemagglutinin Protein, C-His |
|
|
EVV03803 |
Recombinant Influenza A virus HA/Hemagglutinin Protein, C-His |
|
|
YVV03801 |
Recombinant Influenza A virus HA/Hemagglutinin Protein, N-His |
|
|
EVV03805 |
Recombinant H5N1 HA/Hemagglutinin Protein, C-His |
|
|
EVV03806 |
Recombinant Influenza A virus HA/Hemagglutinin Protein, C-His |
|
|
EVV05301 |
Recombinant Influenza B virus HA/Hemagglutinin Protein, C-His |
|
|
EVV24001 |
Recombinant Influenza A virus (H7N9) Neuraminidase/NA Protein, C-Strep |
|
|
EVV24002 |
Recombinant Influenza A virus (H3N2) Neuraminidase/NA Protein, N-His |
|
|
EVV03301 |
Recombinant Influenza A virus NP/Nucleoprotein Protein, C-His |
|
|
YVV03302 |
Recombinant Influenza A virus NP/Nucleoprotein Protein, N-GST & C-His |
|
|
YVV24101 |
Recombinant Influenza A virus PA Protein, N-His-SUMO |
|
|
EVV33801 |
Recombinant Influenza D virus HE/Hemagglutinin-esterase-fusion glycoprotein, C-His |
|
|
Antibody |
PVV03801 |
Anti-Influenza A virus (H5N1) HA/Hemagglutinin Polyclonal Antibody |
|
DVV03801 |
Research Grade Diridavumab |
|
|
DVV03802 |
Research Grade Firivumab |
|
|
DVV03803 |
Research Grade Navivumab |
|
|
DVV03804 |
Research Grade Gedivumab |
|
|
DVV03805 |
Research Grade Lesofavumab |
|
|
DVV03806 |
Research Grade VIR-2482 |
|
|
DVV03807 |
Research Grade Anti-Influenza A virus HA/Hemagglutinin Broad-Neutralizing Antibody (CR9114) |
RSV (Respiratory Syncytial Virus) Proteins and Antibodies for Cutting-Edge Studies
Respiratory Syncytial Virus (RSV) is a leading cause of respiratory infections among vulnerable populations, especially infants and the elderly. AntibodySystem’s RSV proteins and antibodies include:
■RSV Fusion Glycoprotein (F) – Engineered to facilitate studies on viral fusion and entry, commonly used in vaccine research.
■RSV Major Surface Glycoprotein (G) – Key to examining viral binding and immune recognition, supporting antiviral development.
Our RSV portfolio is crafted to offer reliability and reproducibility, accelerating research into RSV pathogenesis and immunity.
Fig 2.Respiratory syncytial virus virion
|
Type |
Catalog No |
Product Name |
|---|---|---|
|
Protein |
EVV02804 |
Recombinant HRSV F/Fusion glycoprotein F0 Protein, C-His |
|
EVV02803 |
Recombinant HRSV Fusion glycoprotein F0 Protein, C-His-Strep |
|
|
EVV08501 |
Recombinant HRSV G/Major surface glycoprotein G Protein, C-His |
|
|
Antibody |
RVV02818 |
Anti-HRSV F Protein Antibody (131-2A) |
|
RVV02816 |
Anti-HRSV-A F/Fusion glycoprotein F0 Antibody (101F) |
|
|
RVV02810 |
Anti-HRSV-A F/Fusion glycoprotein F0 Antibody (5C4) |
|
|
RVV02825 |
Anti-RSV F/Fusion glycoprotein F0 (SAA2058) |
|
|
VVV02806 |
InVivoMAb Anti-HRSV F/F protein Antibody (17E10. T) |
|
|
DVV02808 |
Research Grade Clesrovimab |
|
|
Kit |
KVV02801 |
HRSV F/Fusion glycoprotein F0 Antigen ELISA Kit |
|
KAV02802 |
Anti-HRSV F/Fusion glycoprotein F0 Human IgG ELISA Kit |
Why Choose AntibodySystem for Your Virology Research?
AntibodySystem’s Influenza and RSV proteins and antibodies deliver:
■Proven Quality – Each product is rigorously tested to ensure consistency and reliability.
■Precision Results – Designed for dependable, reproducible outcomes across diverse experimental settings.
■Global Recognition – Trusted by scientists worldwide and featured on leading databases like CiteAb and Biocompare.
Choose AntibodySystem to elevate your research with trusted Influenza and RSV proteins and antibodies. Browse our catalog today to find the exact resources you need to drive discoveries in virology, virus-host interactions, and immune response.
References：
■Battles, Michael B, and Jason S McLellan. “Respiratory syncytial virus entry and how to block it.” Nature reviews. Microbiology vol. 17,4 (2019): 233-245. doi:10.1038/s41579-019-0149-x
■Robinson, Elisabeth, and Rosalind L Smyth. “Preventing respiratory syncytial virus bronchiolitis in infants.” BMJ (Clinical research ed.) vol. 381 1023. 10 May. 2023, doi:10.1136/bmj.p1023
For Research Use Only. NOT FOR CLINICAL USE.
